
Opinion|Videos|September 30, 2024
Exploring Updates in TiNivo-2 From ESMO 2024
Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
Trial Data Show Efficacy, Tolerability of Nivolumab Plus Visogromab in MIBC
3
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
4
Domvanalimab Combo Shows Enriched First-Line Efficacy in Advanced GI Cancers
5









































